SAM
ADMA icon

Smartleaf Asset Management’s ADMA Biologics ADMA Stock Holding History

Smartleaf Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.06K Sell
881
-3,032
-77% -$47.8K ﹤0.01% 2429
2025
Q4 		$71.8K Buy
3,913
+565
+17% +$9.52K ﹤0.01% 1367
2025
Q3 		$49.2K Buy
3,348
+230
+7% +$3.94K ﹤0.01% 1406
2025
Q2 		$56.6K Buy
3,118
+700
+29% +$14.3K 0.01% 1114
2025
Q1 		$49K Buy
2,418
+1,493
+161% +$25.8K ﹤0.01% 1157
2024
Q4 		$16.2K Buy
+925
New +$17.4K ﹤0.01% 1766

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Smartleaf Asset Management's ADMA Position: Q1 2026 in Review

Smartleaf Asset Management reduced its ADMA Biologics (ADMA) stake by 77% in Q1 2026, selling an estimated $47.8K and leaving 881 shares worth $8.06K. The position accounts for ﹤0.01% of the portfolio, ranked #2429.

Smartleaf Asset Management first reported a position in ADMA in Q4 2024 and has held it in 6 quarters since. The position peaked at $71.8K in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Smartleaf Asset Management held 881 shares of ADMA Biologics worth $8.06K as of Q1 2026.
  • Smartleaf Asset Management sold 3,032 ADMA Biologics shares in Q1 2026, an estimated $47.8K.
  • ADMA Biologics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #2429 holding.
  • Smartleaf Asset Management first reported a position in ADMA Biologics in Q4 2024 and has held it in 6 quarters since.
  • Smartleaf Asset Management's ADMA Biologics position peaked at $71.8K in Q4 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.